Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

IMI sticks with guidance as trading momentum picks up in H2

(Sharecast News) - IMI has reiterated its full-year guidance after a broadly stable first half, with the engineering business hailing "strong momentum" heading into the second half. The company, which builds products used in fluid and motion control applications, reported revenues of £1.09bn for the six months to 30 June, down 1% on last year due to currency movements.

However, on an organic basis, revenues rose by 2%, as a 1% fall in the Life Technology business - due to weakness in the life science, fluid control and transport sectors - was outweighed by a 3% improvement in the Automation division.

Operating profits rose 1% to £198m, helped by an improvement in operating margins to 18.2% from 17.9%.

Operating cash flow improved 21% compared with last year to £158m, which IMI said was a result of its "disciplined approach to capital allocation", helping it to raise its interim dividend by 10% to 11p per share.

Looking ahead, the company expects organic revenue growth to pick up to a mid-single digit rate for 2025 as a whole.

"There is strong momentum in our business heading into the second half, underpinned by a record order book in Process Automation, continued strong demand in Climate Control, improving trends and catch-up shipments in Industrial Automation, and supportive order books in both Transport and Life Science & Fluid Control," said chief executive Roy Twite.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.